$NFLX at $65 -$67 This is a buyable retest, not a falling knife — if $65 holds on a weekly closing basis. The 2022 top holding as 2026 support, MACD turning, RSI with headroom — that's a bottoming signature. But respect the line: below $60 on a weekly close, walk away, because then it's not a retest anymore, it's a breakdown.

Energy constraints are real. Data centers need power on a 2-year timeline; generation gets built on a 10-year one. That gap is the trade, and it only pays the early. Early money buys the bottleneck: grid equipment, turbine backlogs, interconnection queues still priced like it's 2023. Position before the crowd does the math.

Most investors ask - what should I buy? Wrong question. The right one: what shape should my portfolio have at MY stage? A $5K account and a $100K account should not own the same things. Get the shape wrong and it costs you years. I just published the full framework — how the portfolio changes at $5K, $25K, $50K, and $100K . Link in bio. Stop guessing, start structuring.

Five speculative names, all washed out, all with enough cash to survive the wait. That's the setup. $QS at $4.57 — 76% off its high, sitting right on the 52-week low. $859M in cash, almost no debt. Burns ~$60M a quarter, so roughly a year of runway — but VW and Honda partnerships are real and cell output is doubling in H2. $SMR at $7.75 — down 81% in a year, 86% off its $57 high. Nuclear is the only baseload answer to the AI power crunch, and the market just forgot. Near the low with the whole sector repricing. $JOBY at $5.95 — at the 52-week low, down 55% this year. $2.3B in cash and investments covers two years of burn. FAA certification is the binary event — Texas flights are the first real-world proof. $SOUN at $5.84 — 74% off its high. Revenue up 45% and accelerating, guidance raised, $200M net cash with almost no debt. The business is working; the stock just isn't. $SERV at $4.62 — 75% off its high, down 56% this year. Delivery robots with Uber DNA, near the low. none of these are healthy in the traditional sense — they all burn cash and dilution is always on the table. What's healthy is the balance sheet relative to the fear: no near-term bankruptcy risk in any of them, and you're buying 70-85% below the highs. This is the bottom-of-the-cycle speculative basket. Small sizes, wide stops, and you only need one or two to work. DYOR

$SOFI at $15.77 — good buy. Down 39% this year, 50% off its peak, sitting near the 52-week low. Meanwhile: revenue +41%, net income +65%, deposits up from zero to $45.5B since the bank charter. You're paying 20x forward earnings for a digital bank growing like a startup. Street target $22.50 — that's 43% upside. Earnings October 27. Fintech gets left for dead every cycle and this is what the bottom looks like. Starter size, add near $15.

The money is rotating into the second layer of the AI value chain. Layer one was $NVDA and the hyperscalers. That money's been made. Layer two is the picks-and-shovels: memory, optics, power, test, storage, foundry. Most trade at half the GPU multiple. The stack: Data: $P — all-flash for the AI pipeline, revenue +38%, just crushed earnings. AI is a data problem before it's a compute problem. Memory: $PENG (earnings Tuesday), $RMBS, The bottleneck nobody can print. Optical/fabric: $AAOI $CIEN $CRDO $MXL $SMTC $ANET $FN. My fabric-shift thesis in one basket. Power: $MPWR. Power density rises every generation and they tax all of it. Test/materials: $AEHR $AXTI $ACLS $ENTG $ONTO. The tollbooths before the fab. Foundry: $GFS. Regionalized supply chains give this strategic value. None of these need AI to work in the abstract. They get paid when racks get built. That's capex you can track — not a narrative.

$VST is buy at $140 $140 , sitting at 6-9% of its 52-week range - $132.66–$217.10 . You're buying 36% below the high on a stock whose fundamentals just got better, not worse. The $4B DOE loan expected announcement Monday funds the nuclear uprates at near-zero political risk — this is the administration's flagship quadruple nuclear by 2050 policy, and Vistra is the vehicle. The $META deal 433 MW of uprate output, deliveries starting 2031 is contracted hyperscaler demand — exactly your energy-constraints thesis playing out in real contracts. CEO put $1.17M of his own money in at $135 — first real buy in 3+ years. He knows the assets better than anyone. Not a financial advice

Good morning! Mistakes increase your experience. Experience decreases your mistakes. The key is not to avoid every mistake—it’s to learn from them. When you learn from your mistakes, your experience becomes someone else’s lesson. Keep learning. Keep growing. Keep moving forward. ❤️

$OUST at $43 — buy. Lidar for autonomy, robotics, and mapping. Revenue growing 40%+, fresh wins with GeoCue and GUSS, down 16% this month on profit-taking after a 50% YTD run. Street says Buy. Still losing money and lidar is a price-war market, so this is a starter position, not a core hold. But washed-out growth hardware with real deals is exactly the setup that snaps back.

5 BIOTECH STOCKS I’M WATCHING Biotech is all about clinical catalysts, cash runway, regulatory progress and execution. These 5 have very different stories, but all have developments worth tracking: $ABCL at $12.63 Platform + pipeline. ABCL635 delivered positive Phase 2 data, while new T-cell engager collaborations with Jazz and Vertex added significant upfront cash and milestone optionality. The next question is whether AbCellera can turn platform validation into multiple valuable clinical assets. $RXRX at $3.83 AI-driven drug discovery. The thesis remains centered on using large-scale biology + AI to accelerate drug development. Multiple clinical programs and pharma partnerships provide catalysts, but cash burn and the ability to translate the platform into successful medicines remain key risks. $PRME at $3.12 Prime Editing + clinical validation. PM577a is moving into a global Phase 1/2 program for Wilson disease, while PM359 and PM647 provide additional clinical catalysts. The big question is whether Prime Editing can demonstrate meaningful human efficacy at scale. $ALT at $3.25 Pemvidutide is now moving into Phase 3 for MASH following positive Phase 2b data. ALT also reported positive Phase 2 AUD data and completed enrollment in its ALD study. The company ended Q2 with $519M in cash, giving it substantial runway for development. $HELP at $12.37 Formerly Cybin, HELP is developing novel serotonergic agonists for mental-health conditions. HLP003 is in Phase 3 for adjunctive MDD and has FDA Breakthrough Therapy Designation, while HLP004 is in Phase 2 for generalized anxiety disorder. Phase 3 execution and upcoming clinical data are the major catalysts. I’m watching across all 5 Clinical data → Regulatory progress → Cash runway → Dilution → Commercial potential These are high-risk biotech names, and a promising platform doesn’t automatically translate into an approved or commercially successful drug. $ABCL $RXRX $PRME $ALT $HELP Biotech could become a very interesting part of the portfolio over the next few years — but position sizing and patience matter. NFA. DYOR.

"The memory trade may be entering a completely different phase.For the last several years, investors have been conditioned to think of memory as a cyclical industry:" Read my latest post on Slice =>

Watching these 10 names across AI compute, edge AI, networking, optics, manufacturing and power: 1. $CRDO My first name to investigate for the AI connectivity angle. AECs, optical connectivity and high-speed interconnects are becoming increasingly important as AI clusters scale. Credo says its AECs can materially reduce power consumption versus laser-based alternatives. 2. $AAOI Higher risk, but potentially much higher operating leverage if its optical products gain share as AI data-center bandwidth requirements increase. This is more speculative than CRDO. 3. $LITE A direct way to play optical infrastructure, including optical circuit switching and photonics. Its collaboration with Marvell is specifically targeting next-generation AI infrastructure. 4. $MRVL Less speculative than several names above, but still interesting because it sits directly in the connectivity layer. Marvell is targeting switching, optical interconnect, PCIe and CXL memory solutions across AI infrastructure. 5. $COHR Another photonics/optical play. Potential upside comes from increasing bandwidth requirements and next-generation optical architectures. 6. $CLS The less-obvious infrastructure play. It participates in the manufacturing and systems layer behind hyperscale/AI infrastructure. Worth watching for continued AI-related revenue growth. 7. $QCOM This is the edge-AI + data-center convergence play. Qualcomm recently announced a multigenerational collaboration with Amazon involving customized AI silicon and optical connectivity for AWS. 8. $AMD A broader AI-compute opportunity spanning data centers and increasingly AI PCs/edge devices. The upside case doesn’t depend entirely on edge AI. 9. $VRT Not an edge-AI company, but potentially one of the strongest picks-and-shovels around the physical constraint: power + cooling. As AI racks become increasingly power-dense, thermal and electrical infrastructure become more important. 10. $GEV The power-grid side of the thesis. AI data centers need electricity, and GEV has exposure to generation and electrification infrastructure. S&P Global expects AI/data-center demand to contribute to increased investment in power infrastructure.